Cancer peptide therapeutics

Details Cancer peptide therapeutics Cancer peptide therapeutics

A - Human Necessities

61

K

A61K 38/08 (2006.01) C12N 15/62 (2006.01)

Patent

CA 2732737

Peptide variants corresponding to cancer specific isoform of proliferating cell nuclear antigen (caPCNA) interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. Cell-permeable caPCNA-derived peptides and their variants serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment cytotoxic effects of existing cancer therapy. These compositions are also useful for chemoprevention of cancer.

La présente invention concerne des variantes peptidiques correspondant à une isoforme spécifique au cancer d'antigène nucléaire de prolifération cellulaire (caPCNA), qui interfèrent avec l'interaction protéine-protéine intracellulaire, entraînant ainsi une réduction du potentiel prolifératif du cancer. Des peptides dérivés de caPCNA perméables aux cellules et leurs variantes servent de compositions thérapeutiques pour réduire la prolifération de cellules cancéreuses, et pour augmenter les effets cytotoxiques de la thérapie cancéreuse existante. Ces compositions sont également utiles pour la chimioprévention du cancer.

Affiliated with

Also associated with

Rating

Cancer peptide therapeutics does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer peptide therapeutics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer peptide therapeutics will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1726766